Board Management Nancy Falls Board Management Nancy Falls

8 Technology Trends That Are Impacting the Clinical Trial Space

Technology’s impact on clinical trial management touches patient recruitment and retention, study design and execution, and compliance and reporting. Here are 8 technology trends affecting the clinical trial space.

Technology’s impact on how clinical trials are managed is profoundly changing how treatments move from research and development to market. This seismic change impacts everything from patient recruitment and retention to study design and execution, as well as affecting compliance and reporting results. Understanding how these trends shape the trial management process can help you successfully navigate this changing landscape. 

Here are eight technology trends changing the pharmaceutical - and thus clinical trial - space. 

8 Tech Trends Impacting Clinical Trial Management

Data Accessibility

One critically important trend that’s coming into focus for drug makers is that patients are increasingly taking control of their healthcare decisions and expectations around treatment options. As a result, they now have more access to information than ever before – including data on both existing approved therapies and experimental drugs through online patient support groups, online media, and social networks. 

This access to information has empowered patients to be more informed about the different options available to them, which in turn helps drive greater involvement in their clinical care decisions and trial involvement. 

Artificial Intelligence

Another key trend driving change in the clinical trial space is the increased use of artificial intelligence (AI). Traditionally, AI was used primarily for data analysis and machine learning. Today it’s being applied across various aspects of drug development – from reducing costs, improving patient outcomes, enhancing early-stage research and streamlining trial processes. 

For example, using AI to predict issues or potential adverse events during clinical trials can help reduce development timelines while also improving patient safety.

Virtual and Augmented Reality

In addition to AI, other emerging technologies are having a major impact on clinical trials – namely, virtual and augmented reality (VR/AR). These immersive technologies have the potential to revolutionize many aspects of the drug development process – from patient recruitment and engagement to improving study design. For example, VR may help enhance patient comprehension and retention by immersing participants in simulated environments that mimic trial processes. On the other hand, AR could be used to enable remote monitoring of subjects during home-based trials.

Blockchain Technologies

Blockchain technologies are also poised to disrupt the pharmaceutical industry. The use of blockchain in clinical trials offers a number of advantages that can help increase both transparency and data security. As an example, by creating a distributed ledger for each trial participant’s clinical data, it would be possible to share this information with authorized parties – such as patients and researchers – while still maintaining confidentiality. In addition to these benefits, blockchain could also help pharmaceutical companies streamline clinical trial management processes and improve patient retention rates.

Cybersecurity

While each of these trends offers tremendous potential for improvements in clinical trials, it’s essential to keep in mind that they also bring new challenges and risks. As drug makers continue to embrace innovative technologies and processes, the need for proper data security has never been greater. 

Ensuring that appropriate cybersecurity measures are in place will help avoid potentially devastating data breaches – such as those that have recently occurred at some major pharmaceutical companies. 

Continuous Drug Production

Continuous drug production, also known as continuous manufacturing, is a newer methodology that enables the creation of pharmaceuticals in large quantities at any time. In contrast with traditional batch production methods that take weeks or months to complete, continuous processing allows manufacturers to produce drugs continuously and more quickly. 

Due to their shorter development timelines and lower cost structures compared with legacy pharmaceutical companies, innovative biotechnology firms are taking charge of this initiative. However, even traditional drug makers are beginning to explore adopting this new tech. 

This trend will lead to an increased number of generic drugs becoming available and further price pressure on branded medications already in the market. Additionally, as biopharma companies invest significantly in R&D for biosimilars (generic therapeutic proteins), the potential for these drugs to become available more quickly will also increase.

Telemedicine

The use of telemedicine in clinical trials has been steadily increasing throughout the last few years, and it shows no signs of slowing down anytime soon. With its ability to reduce clinical trial timelines by bringing together patients and physicians at remote locations, this tech trend is likely to become increasingly prevalent in pharma R&D.  

As drug makers continue to refine their approaches using virtual physician consultations, they are expected to realize more cost savings while simultaneously improving patient outcomes. Moreover, as new regulatory rulings enable medical device and smartphone companies to directly market their products for clinical use, the potential for telemedicine to become an integral part of clinical trials will only continue to grow.

Big Data

In recent years, big data analytics have begun playing an increasingly important role in driving advancements in healthcare. As pharmaceutical companies leverage this technology to mine patient data and generate insights into disease progression, they may be able to predict drug efficacy and safety earlier in development more accurately. 

Additionally, by using historical trial data along with real-world evidence from electronic health records (EHRs), researchers can gain valuable information on how patients managed their conditions outside of clinical research settings – and ultimately design more effective clinical trials. By embracing big data analytics at all stages of R&D, drug makers can gain valuable insights that may help them streamline the trial design and enrollment process and improve overall study execution.

Overall, there are several exciting tech trends currently reshaping the space While these trends present new challenges for clinical trial managers, they also provide an opportunity to deliver life-changing drugs and treatments more quickly than ever before. By proactively addressing these risks with appropriate technology measures in place, clinical trial managers can confidently navigate this changing landscape and successfully advance their trials through development and onto the market.​

Get Ready for The Future of Clinical Trial Management with Cloud Concinnity 

Cloud Concinnity was specifically built to meet the  need for more efficient, effective clinical trial management. Our cloud-based integrated platform centralizes, simplifies, and automates control of data, communications, process management & reporting while unlocking the value of big data.

What does this mean for you? 

Our clinical trial solutions enable sponsors and CROs to effectively manage large, complex trials. We allow you to reduce operational costs, eliminate data entry errors & increase the speed of decisions with one centralized platform that can be accessed anytime, anywhere. Our intuitive interface is designed to enable users to quickly understand their roles and responsibilities while taking advantage of automated processes. 

The result, more efficient processing, a stronger ROI, and a better quality of life for your workforce. 

 Learn more about Cloud Concinnity and schedule your demonstration today

Read More
Board Management Concinnity Board Management Concinnity

5 Biases That Hold Boards Back

In today’s business world, chaos often feels like the new normal. To stay on top of it all, growth and change are not optional — they need to be the focus of an ongoing conversation for every board of directors. Too often we see stale, stagnating biases hold boards back from taking new opportunities by the horns and turning the page. Today, we examine 5 biases that every board director can look for to get that conversation started within their own team.

In today’s business world, chaos often feels like the new normal. To stay on top of it all, growth and change are not optional — they need to be the focus of an ongoing conversation for every board of directors.

Too often we see stale, stagnating biases hold boards back from taking new opportunities by the horns and turning the page. Here are 5 of those biases every board director can look for to get that conversation started.

  1. Defend & Extend Mentality. When a board focuses too closely on defending and extending the “core” business strategy of the company, the world will pass you by. While taking care of the core is always a good idea, it should be in the DNA of every board director to offer an outside perspective, be a disruptive thinker, and act as a voice for change. Think about the directors on your board — how often is someone bringing up new, disruptive ideas? How many of your conversations are anticipating where your industry will be years down the line?

  2. Traditionalism. The first time someone on your board justifies a process or an action step with “…Because we’ve always done it this way,” you can be sure that everyone needs to take a step back and reassess. While there is nothing wrong with preserving tradition or holding onto processes and rituals that work, a problem arises when the board defaults to believing that things are better because they are traditions. In a world evolving as rapidly as ours, not every tradition can endure. Is your board holding onto any traditions (like board books or committee processes) that used to work but need to be updated?

  3. Baby Boomer. This one is a media favorite that can be easy to exaggerate, but the bias here can be insidious. When boomers believe (consciously or subconsciously) that they and other Boomers know best, the board is in some trouble. Today’s boards need a diversity of opinion to thrive — and that means across gender, race, and age. Look around your board — is everyone a Baby Boomer? If so, it’s time to start the hard conversations.

  4. Technophobia. People fear technology for many reasons. Adopting new tech can be challenging, especially for those who spent the first 20 years of a career without it. It means investing time into a new system, taking many board directors out of their comfort zone at a time in their careers when they are used to being experts. Some people are (rightly) wary of ever-evolving cyber-risk. But at this point in business, avoiding tech puts any team at a gigantic disadvantage, severely limiting the options of boards who need to be agile in the face of business chaos. Tech has been the enabler of product transformation, marketing opportunities, data analysis and process innovation. An understanding of its possibilities is critical for strategic thinking. Look at how your board does business — is it utilizing tech wherever it can? Or is it resisting new tools that are revolutionizing what today’s leaders can do?

  5. Board Stagnation. Everyone wants to hold on to a good gig and do their part, but being afraid of rotating in new people and refreshing a board’s makeup is the beginning of decay. Forgetting to prioritize fresh perspectives and new blood can creep up on even the best teams. The solution is implementing a regular review process and considering term limits for board directors. Even if you’re not bringing in new board directors every year, you can bring in outside experts or coaches to stir the pot. Think about the last few years on your board — has much changed? And if not, what can you do to drive what’s next?

These are not the only biases that can drag on a board, but they are prime examples of the kind of thinking that can hold a company back. We all have things to uncover about ourselves and our teams that are hindering our business growth. The point is not to ask yourself which of these are holding your board or company back — the point is to have an ongoing conversation among your leadership about what can be done to keep everyone moving forward and not get caught in the inertia of bias.

Cloud Concinnity® is a powerful tool for transcending these biases. It is a software platform custom built for today’s connected leaders, who must facilitate the complex processes required to manage and govern today’s companies. It makes real change possible by providing a forum for important conversations. It brings together the best of process management tools, board management software, team collaboration and GRC software into one central, simple, secure hub.

In a world where chaos is the new normal, Cloud Concinnity® gives boards, c-suites, and investors the power to be as agile as they need to be. Click here to learn more about how the right tool can help your team transcend hidden bias and finally start having the important conversations.

Read More